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Abstract
Background: Leprosy can be cured, but physical disability (PD) as a result of the infection can progress in the post-
release from treatment phase. This study evaluated the likelihood of, and factors associated with, the progression of
the PD grade post-release from treatment among leprosy patients treated in Cáceres-MT, Brazil in the period 2000
to 2017.
Methods: A retrospective cohort study and survival analysis were performed in the hyperendemic municipality of
Cáceres in the state of Mato Grosso. The study population consisted of newly diagnosed leprosy patients released
from treatment between January 1, 2000 and December 31, 2017. The main outcome was the progression of the
PD grade with regard to probability and time; and the evaluated covariates included clinical, operational and
demographic variables. The Cox proportional risk model was used to estimate the risk ratio (Hazard Ratios) of the
covariates. Both an univariate and a multivariate analysis were implemented, with 95% confidence intervals.
Results: The mean time for progression of the PD grade was 162 months for PB and 151 months for MB leprosy
patients. The survival curve showed that 15 years after the release from treatment, the probability of PD grade
progression was 35%, with no difference between PB and MB or age groups. Leprosy reactions and registered
medical complaints of any kind during treatment were identified as risk factors with Hazard Ratios of 1.6 and 1.8
respectively.
Conclusions: People released from treatment as cured of leprosy are susceptible to worsening of the PD, especially
those who have had complications during multi-drug therapy treatment. This indicates that leprosy patients should
be periodically monitored, even after the successful completion of multidrug therapy.
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Background
Physical disability (PD) can occur before leprosy diagno-
sis, during treatment and post-release from treatment
[1]. However, although patients may be exposed to risk
factors that potentiate the risk of more severe PD [2, 3]
they stop being routinely evaluated once the treatment
of active leprosy has been completed [4]. Any worsening
of the PD of leprosy patients post-release from treatment
is worrying, and a lack of comprehensive and systematic
follow-up health care can leave cured leprosy patients
neglected and vulnerable [3]. Many patients are released
from treatment with leprosy reactions and neural im-
pairment [5, 6] but are then excluded from active review
of their disease status and adequate management of their
conditions [7]. In Brazil, newly diagnosed leprosy pa-
tients are systematically recorded and monitored during
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: Peter.steinmann@swisstph.ch
4Swiss Tropical and Public Health Institute (Swiss TPH), Basel, Switzerland
5University of Basel, Basel, Switzerland
Full list of author information is available at the end of the article
Santos et al. Infectious Diseases of Poverty            (2020) 9:53 
https://doi.org/10.1186/s40249-020-00669-4
multidrug therapy (MDT) and are considered cured at
the end of treatment according to the paucibacillary
(PB) or multibacillary (MB) treatment protocol, depend-
ing on the initial diagnosis [7]. In the period following
release from treatment, the prevention of PD is based on
self-care and patients are instructed to self-refer to
health services in case they detect signs and symptoms
of neural impairment [7].
The relevance of PD among leprosy patients is widely
acknowledged. It is also well known that it can occur
post-release from treatment either due to late detection
[2, 8], late onset of leprosy reactions [3, 5, 9] or in the
absence of qualified and timely assistance [10]. The lack
of adherence to recommended self-care for prevention
of PD as another contributing factor during treatment
[11] and post-discharge has also been documented [12].
Unfortunately, the period post-discharge appears to be of
minor concern to health authorities as indicated by the
limited space and attention it receives in the guidelines on
the recommended activities to prevent PD [7, 13].
According to WHO statistics for 2017, the number of
leprosy cases diagnosed with grade 2 PD declined glo-
bally. The exception were five countries including Brazil
where the figure increased by 10% over the previous year
[14]. The Global Leprosy Strategy 2016–2020 has set as
one target the reduction of leprosy cases with grade 2
PD to less than 1 per million inhabitants [15]. Of note,
the leprosy burden is calculated based on the Disability-
Adjusted Life Year (DALY) indicator, that combines
mortality and morbidity information to measure the im-
pact of disease on population health [16]. As leprosy is
associated with low mortality, PD represents the main
burden of disease due to leprosy, but the indicator only
covers information collected at diagnosis and during
treatment whereas the period post-release from treat-
ment is not included [2, 8].
Considering the thousands of leprosy patients treated
and released from treatment annually, and the long-term
consequences of PD, the aim of this study was to evalu-
ate the likelihood and factors associated with the pro-
gression of the PD grade post-release from treatment
among leprosy patients in Cáceres-MT, Brazil in the
period 2000 to 2017.
Methods
Study population and data sources
All leprosy patients treated and cured at the referral cen-
ter for leprosy patients and eight urban units of the Pri-
mary Health Care System in the city of Cáceres were
included in a retrospective cohort study and survival
analysis with months as the unit of time. Cáceres is lo-
cated in the western region of the state of Mato Grosso,
the most leprosy-endemic state in Brazil and bordering
the states of Mato Grosso do Sul, Goiás and Pará. It also
shares an international border with Bolivia. As it is the
case throughout Brazil, leprosy care is decentralized to
the primary care facilities, with support by leprosy refer-
ence centers.
Release from treatment is defined as the end of treat-
ment with MDT [7]. It is recorded as exit by cure in the
leprosy monitoring bulletin in the National Information
System of Notifiable Diseases (SINAN) [17].
The study population consisted of newly diagnosed
leprosy patients who were released from treatment be-
tween 1 January 2000 and 31 December 2017. The study
included mainly patients living in urban areas, all diag-
nosed and treated in the municipality and with a record
of the assessment of the PD grade at diagnosis and at re-
lease from treatment. Exclusion criteria for the study
were cases of grade 2 physical disability (G2D) at release
from treatment because they already had the highest dis-
ability grade, according to the criteria of the Ministry of
Health - Brazil [7, 18]. Follow-up losses were due to ad-
dresses which could not be verified, death, relocation
outside the study area, and refusal to participate in the
study.
Variables
The progression of the PD grade in the post-release
from treatment period was defined as main outcome of
the study. The term “progression” represents any wors-
ening or advance in the PD and consequently, non-
progression represents the maintenance or reduction of
the PD grade. The considered covariates were: gender
(male and female); educational level (illiterate, elemen-
tary school, high school, higher education and missing);
age group (6–15, 16–29, 30–59 and 60 and more years);
leprosy classification (PB and MB); leprosy reactions
during treatment (yes/no); leprosy-related medical com-
plaints during treatment (yes/no).
The addresses registered in the medical records and
complementary information by the Community Health
Workers and other health workers supported the identi-
fication of the current location of the participants. Data
were obtained from medical records and a simplified
neurological evaluation, and registered in a spreadsheet.
The simplified neurological assessment was performed
to determine the current (= time of the study) grade of
PD pertaining to the eyes, hands and feet [7]. Thus, the
time between release from treatment and the assessment
varied between participants. The single assessment was
performed in a health facility near the participants’ resi-
dence, by trained health workers supported by the re-
searchers with experience in neurological assessment of
leprosy patients. The PD grade was classified as follows:
grade 0–G0D (no leprosy-related physical disability),
grade 1–G1D (decreased strength and/or loss of sensa-
tion) and grade 2–G2D (presence of visible disabilities
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and deformities) [7, 13]. Individuals with open lesions
requiring immediate care received assistance at home
and, when necessary, were referred for care at the health
unit closest to their residence.
The follow-up time was recorded in months and defined
as the period between the date of release from MDT treat-
ment and the post-discharge neurological assessment.
Statistical analysis
The Chi-square test was used to evaluate the proportion
difference between covariates. To estimate Hazard Ratios
(HR) of covariates, in both the univariate and multivari-
ate analysis, the Cox proportional risk model was used,
and 95% confidence intervals (95% CI) were calculated
using the Wald test for each covariate. In the final model
the adjusted variables were considered as well as the
overall chi-square. Survival curves were constructed
using the Kaplan-Meier method to assess the likelihood
of leprosy PD progression in the post-release from treat-
ment period. The log-rank test was used to evaluate the
differences between the MB and PB groups regarding
the delay until progression of the PD grade. Individuals
who did not show progression of the PD grade and those
not evaluated at follow-up (lost at follow-up) were cen-
sored at the end of the study. Statistical analysis was per-
formed using the Statistical Package for the Social
Sciences program (SPSS version 22.0; IBM Corp.,
Armonk, NY, USA).
The study was approved by the Ethics Committee of
the Hospital Universitário Júlio Muller (authorization
number 555567; 02/26/2014). All participants signed a
Consent Form after they had received an oral and writ-
ten explanation of the study during a visit to their home
by a researcher and health workers.
Results
Study cohort characteristics
Among the 618 potential participants initially considered
eligible for inclusion in the study, 62.3% (n = 385) could
be located and agreed to the assessment of the PD grade
in the frame of the study. Unavailable potential partici-
pants were not located at the recorded address (20.4%),
moved out of the municipality (10.5%), had died (6.5%)
or refused to participate in the study (0.3%; Fig. 1).
No statistically significant differences with regard to
gender, age group or operational leprosy classification
were observed between the final study cohort and the
patients lost to follow-up (Table 1).
Risk of physical disability grade progression
The Cox proportional risk model indicated no signifi-
cant difference in the risk of progression of the PD grade
post-release from treatment between age groups and op-
erational leprosy classifications. Leprosy reactions during
the treatment period represented a 1.6 times greater risk
of PD progression (HR: 1.6; 95% CI: 1.1–2.4). A record
Fig. 1 Flowchart of the follow-up of a cohort of leprosy patients released from treatment in Cáceres-MT, Brazil, in the period 2000 to 2017.
Potentially eligible were individuals with an assessment of the physical disability grade at diagnosis and release from MDT treatment who were
still living in Cáceres at the time of the study
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of leprosy-related complaints during treatment was asso-
ciated with almost twice the risk of progression of the
PD post-release from treatment (HR: 1.8; 95% CI: 1.3–
2.4; Table 2).
The mean time for progression of the PD grade was
162 months for PB and 151 months for MB. The survival
curve shows that after release from MDT treatment the
risk of PD grade progression was similar for patients
with PB and MB leprosy (P-value > 0.05; Fig. 2).
The mean time until progression of the PD grade was
130 months for patients with documented leprosy reac-
tions during treatment. For individuals with recorded
complaints during treatment the average time of pro-
gression of the PD grade was 139 months.
Discussion
Our study shows that the cumulative probability of pro-
gression (worsening) of the PD grade of people treated
and bacteriologically cured of leprosy increases with
time. After 10 years this probability was 30%, and after
15 years it was 35% in a cohort of patients from Mato
Grosso, Brazil. The risk of disability progression is asso-
ciated with leprosy reactions and the presence of triggers
for complaints during the MDT treatment phase. It is
possible that some individuals rated with more severe
PD at follow-up compared to the moment when they
were released from treatment developed this condition
before or during treatment, but it went unrecorded.
However, particularly G2D (more severe) is character-
ized by visible deformities, generally precluding classifi-
cation errors.
Peripheral neuropathies can be irreversible and cause
emotional, social and economic problems to those
Table 1 Comparison of key characteristics between the final
study cohort of leprosy patients and potential study participants
from Cáceres - MT, Brazil (index patients released from
treatment in 2000 to 2017)
Variables Final study cohort
n (%)
Lost to follow-up
n (%)
χ2 P-value
Gender
Male 200 (59.3) 137 (40.7) 2.747 0.097
Female 185 (65.8) 96 (34.2) 1 -
Age group (years)
6–15 18 (51.4) 17 (48.6) 0.396 0.528
16–29 76 (58.0) 55 (42.0) 0.487 0.484
30–59 234 (66.3) 119 (33.7) 3.088 0.078
60 + 28 (28.3) 71 (71.4) 1 -
Operational classification
Paucibacillary 252 (60.7) 163 (39.3) 1 -
Multibacillary 133 (65.5) 70 (34.5) 1.334 0.248
-: Not applicable.
Table 2 Hazard Ratio (HR) and 95% confidence intervals (CI) for the progression of the physical disability grade among leprosy
patients in the post-release from treatment period, Cáceres - MT, Brazil (index patients released from treatment in 2000 to 2017)
Variables Progression
(n)
Crude HR
(95% CI)
P-value* Adjusted HR (95% CI)a P-value*
Gender
Male 103 1.06 (0.79–1.41) 0.689 - -
Female 85 1 -
Age group (years)
6–15 9 1 - -
16–29 27 0.78 (0.36–1.66) 0.525 -
30–59 123 1.53 (0.78–3.02) 0.213 -
60 or older 29 1.23 (0.58–2.61) 0.579 -
Operational classification-
Paucibacillary 123 1 - -
Multibacillary 65 0.82 (0.60–1.11) 0.198 -
Leprosy reaction during treatment
Yes 71 2.09 (1.55–2.82) 0.001 1.65 (1.13–2.40) 0.008
No 116 1 1
Complaints during treatment
Yes 82 2.01 (1.49–2.70) 0.001 1.76 (1.29–2.40) 0.001
No 102 1 1
a Variables adjusted by leprosy reaction during treatment, complaints during treatment
* P-value according to Wald test
-: Not applicable; HR - Hazard ratio; CI - Confidence interval.
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affected [19]. Preventing disability is one of the priorities
of the Global Leprosy Strategy. The emphasis of the
WHO strategy is early detection to prevent cases with
G2D at the time of diagnosis [15]. The relevance of early
detection as an approach to reduce the risk of develop-
ing disabilities is undisputed [20]. Studies conducted in
the post-release from treatment period showed that early
diagnosis is associated with reduced risk of PD [2, 8, 21].
On the other hand, any delay in starting treatment in-
creases the risk of PD developing in the post-release
period [8]. Descriptive studies conducted in India and
Nigeria [6, 22], in Brazil [3, 19, 23] and specifically in
Mato Grosso [24] confirm our findings of considerable
PD developing after treatment completion. For this rea-
son, disability prevention measures including regular
medical review of the former patients are recommended
to continue after the completion of the MDT treatment.
For this, primary care would need to be restructured to
ensure the provision of standardized and quality services
post-release from treatment [7, 25].
Our findings are also corroborated by observations on
the cohort of MB leprosy patients treated at the
Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro.
A 40% probability of progression of PD 10 years after
MDT completion has been documented for this group.
The main difference between the two cohorts is that the
present study followed up MB and PB patients in a hy-
perendemic area of Brazil who had been treated in pri-
mary care while the study by Sales et al. [2] focused on
the follow-up of patients seen by referral service. This
patient population tends to be more severely affected
when compared to those treated by the primary care ser-
vices. Indeed, Rio de Janeiro is considered low endemic
for leprosy; however, the average patients have more se-
vere complications when compared to their peers from
Mato Grosso. From 2012 to 2016, the average new case
detection rate (NCDR) in Rio de Janeiro was 7.2 cases
per 100 000 inhabitants; in the same period, the rate of
patients with G2D was 7.4 cases per 1 million inhabi-
tants. In Mato Grosso, the NCDR was 88.9 per 100 000
inhabitants and the rate of patients with G2D was 446.6
cases per 1million inhabitants over the same period [26].
It is noteworthy that the multivariate analysis showed
no significant difference between PB and MB cases with
regard to the rate of PD progression. Of note, the classi-
fication of leprosy patients had to be taken at face value
and could not be independently verified. Operationally,
this means that all leprosy patients have a potential to
develop PD post treatment completion and need to be
considered in efforts to prevent leprosy sequelae. It is
thus important to launch disability prevention activities
for all patients, regardless of the clinical form and the
treatment status.
Leprosy reactions are the main risk factor for the de-
velopment of PD during [5, 22] and after treatment [6].
Our findings show that the occurrence of leprosy reac-
tion episodes during MDT treatment increases by 96%
the risk that the disability grade progresses to a more
serious stage post-release from treatment. This corrobo-
rates findings by others [3, 8, 27]. In contrast, a study of
treated MB leprosy patients revealed no association be-
tween leprosy reactions and the development of new dis-
abilities, possibly suggesting that the worsening of the
PD grade in the post-release period depends on the clin-
ical management of cases during treatment [2].
Our findings show no association between age and the
worsening of the PD grade in the post-release from
treatment period, in accordance with other studies [2,
8]. Age may reflect late diagnosis and delayed treatment,
which are the main causes of PD in adults [8] but appar-
ently does not influence in itself the worsening of PD
after treatment.
The development of PD can result in reduced physical
capacity, the latter being essential for many professional
activities [24]. It can thus render individuals more sus-
ceptible to unemployment and socially vulnerable [4,
28]. Being unemployed can interfere with people’s qual-
ity of life, compromise the self-support and financial
maintenance of the family, causing social, psychological
and economic problems [29]. Studies in India [30] and
Brazil [3, 10] have described these relationships in detail.
Adherence to regular practice of self-care is low in
former leprosy patients due to stigma, lack of knowledge
about leprosy, inability to perform activities and lack of
Fig. 2 Survival curve for PD grade progression post-release from
MDT treatment for MB and PB leprosy patients released from
treatment in 2000–2017; Cáceres – MT, Brazil
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commitment to health [9]. The participation of cured pa-
tients in a self-care group contributes significantly to the
acquisition of knowledge and improves self-care practices
[31]. In Mato Grosso, there are currently no self-care
groups in a majority of municipalities. After release from
MDT treatment, people are no longer regularly seen by
the health services and are advised to only return when
identifying a neural disorder [7]. This recommendation
may not be appropriate considering the socioeconomic
profile of people who develop PD due to leprosy. Gener-
ally, the affected population has limited education and in-
come [3, 19, 32], factors that may interfere with the
understanding of the concept of self-care, with self-
observation and with treatment seeking behavior [3].
Whereas reducing PD at the time of diagnosis is cur-
rently a priority for WHO and many countries [15], it is
necessary to reorganize leprosy programs to offer care for
all individuals affected by the disease, including those re-
leased from MDT treatment. The post-release care
process should be standardized and the care structure
available in the primary care network improved in view of
the continuing demand for these services [3, 4, 23]. Of
note, such services must complement self-care and -check
by those affected by the disease but released from treat-
ment to jointly contribute to the prevention of PD [11].
The Brazilian guidelines on leprosy patient care as well
the training for leprosy prevention, diagnosis and treat-
ment suggest a simplified neurological assessment. For
this study, the PD grade assigned by the health services
at the time of the assessment was used. The accuracy of
these assessments is unknown. Also, changes in the PD
not warranting a re-classification of the PD grade were
not considered in the study.
Conclusion
The risk of worsening physical disabilities due to leprosy
over a 15 year follow-up period is high. Indeed, more
than one third of the individuals treated and registered
as cured by health services in a hyperendemic area in
Brazil showed clear signs of PD worsening. Especially
people released from treatment as cured but who have
had complications during treatment with MDT are at
risk. Leprosy patients should be regularly examined for
signs of disability even after the completion of MDT.
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